KBC Group’s Heron Therapeutics HRTX Stock Holding History

KBC Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-289,269	Closed	-$576K	–	1845
2024 Q3	$576K	Hold	289,269	–	–	﹤0.01%	709
2024 Q2	$1.01M	Hold	289,269	–	–	﹤0.01%	661
2024 Q1	$801K	Hold	289,269	–	–	﹤0.01%	689
2023 Q4	$492K	Hold	289,269	–	–	﹤0.01%	746
2023 Q3	$298K	Hold	289,269	–	–	﹤0.01%	782
2023 Q2	$336K	Hold	289,269	–	–	﹤0.01%	812
2023 Q1	$437K	Hold	289,269	–	–	﹤0.01%	800
2022 Q4	$723K	Hold	289,269	–	–	﹤0.01%	721
2022 Q3	$1.22M	Sell	289,269 -332,964	-54%	-$1.3M	0.01%	641
2022 Q2	$1.74M	Buy	622,233 +146,600	+31%	+$589K	0.01%	571
2022 Q1	$2.72M	Hold	475,633	–	–	0.01%	522
2021 Q4	$4.34M	Buy	475,633 +23,483	+5%	+$240K	0.01%	475
2021 Q3	$4.83M	Buy	+452,150	New	+$5.5M	0.02%	479
2019 Q4	–	Sell	-550	Closed	-$10K	–	1519
2019 Q3	$10K	Buy	550 +150	+38%	+$2.76K	﹤0.01%	1459
2019 Q2	$7K	Hold	400	–	–	﹤0.01%	1446
2019 Q1	$10K	Hold	400	–	–	﹤0.01%	1393
2018 Q4	$10K	Sell	400 -100	-20%	-$2.75K	﹤0.01%	1292
2018 Q3	$16K	Hold	500	–	–	﹤0.01%	1372
2018 Q2	$19K	Hold	500	–	–	﹤0.01%	1268
2018 Q1	$14K	Hold	500	–	–	﹤0.01%	1257
2017 Q4	$9K	Buy	+500	New	+$8.15K	﹤0.01%	1249

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

KBC Group's HRTX Position: Q4 2024 in Review

KBC Group sold out of Heron Therapeutics (HRTX) in Q4 2024, closing a stake of 289,269 shares — an estimated $576K sold.

KBC Group first reported a position in HRTX in Q4 2017 and held it in 21 quarters. The position peaked at $4.83M in Q3 2021. 161 funds tracked by Wall St. Rank hold HRTX as of Q4 2024.

KBC Group reported no remaining Heron Therapeutics position as of Q4 2024 after selling out during the quarter.
KBC Group sold 289,269 Heron Therapeutics shares in Q4 2024, an estimated $576K.
KBC Group first reported a position in Heron Therapeutics in Q4 2017 and held it in 21 quarters.
KBC Group's Heron Therapeutics position peaked at $4.83M in Q3 2021.
161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2024.

Based on KBC Group's 13F filing for Q4 2024, filed 22 Jan 2025.